AU1622801A - Sustained drug delivery from structural matrices - Google Patents

Sustained drug delivery from structural matrices

Info

Publication number
AU1622801A
AU1622801A AU16228/01A AU1622801A AU1622801A AU 1622801 A AU1622801 A AU 1622801A AU 16228/01 A AU16228/01 A AU 16228/01A AU 1622801 A AU1622801 A AU 1622801A AU 1622801 A AU1622801 A AU 1622801A
Authority
AU
Australia
Prior art keywords
drug delivery
sustained drug
structural matrices
matrices
structural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16228/01A
Inventor
Elly Liao
David J. Mooney
Martin C. Peters
Thomas P. Richardson
Lonnie D. Shea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16619199P priority Critical
Priority to US60166191 priority
Application filed by University of Michigan filed Critical University of Michigan
Priority to PCT/US2000/031754 priority patent/WO2001035932A2/en
Publication of AU1622801A publication Critical patent/AU1622801A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
AU16228/01A 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices Abandoned AU1622801A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16619199P true 1999-11-18 1999-11-18
US60166191 1999-11-18
PCT/US2000/031754 WO2001035932A2 (en) 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices

Publications (1)

Publication Number Publication Date
AU1622801A true AU1622801A (en) 2001-05-30

Family

ID=22602185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16228/01A Abandoned AU1622801A (en) 1999-11-18 2000-11-17 Sustained drug delivery from structural matrices

Country Status (2)

Country Link
AU (1) AU1622801A (en)
WO (1) WO2001035932A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227792B2 (en) * 2001-02-05 2007-12-13 Industrial Technology Research Institute Methods and devices for tissue repair

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
AUPR289601A0 (en) * 2001-02-05 2001-03-01 Commonwealth Scientific And Industrial Research Organisation Method of tissue repair
GB0115320D0 (en) 2001-06-22 2001-08-15 Univ Nottingham Matrix
CA2527578A1 (en) * 2003-06-06 2004-12-16 Humanautocell Gmbh Matrix, cell implantation and method for their production and use
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2008526749A (en) * 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド Delivery of controlled release of pdgf using peptide nanofibers self assembly
CA2632630C (en) 2005-12-13 2016-12-06 President And Fellows Of Harvard College Scaffolds for cell transplantation
AU2007212273B2 (en) 2006-02-09 2013-10-10 Biomimetic Therapeutics, Llc Compositions and methods for treating bone
EP2049145B1 (en) 2006-06-30 2018-03-14 BioMimetic Therapeutics, LLC Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
ES2358703B1 (en) * 2007-11-14 2012-03-21 Universidad Del Pais Vasco Employment of micropart�? culas for use as vaccines and the release of biologically active molecules.
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (en) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Continuous cell programming device
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
JP5816553B2 (en) 2008-09-09 2015-11-18 バイオミメティック セラピューティクス, エルエルシー Platelet-derived growth factor compositions and methods for treating tendon or ligament injury
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
WO2011163669A2 (en) * 2010-06-25 2011-12-29 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA2833385A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
JP6062426B2 (en) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ In situ antigen-producing cancer vaccine
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
WO2013158673A1 (en) 2012-04-16 2013-10-24 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4085341B2 (en) * 1997-03-31 2008-05-14 ザ、リージエンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン Biodegradable matrix of open pores
WO1999058656A2 (en) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Sustained dna delivery from structural matrices
AU4173000A (en) * 1999-03-19 2000-10-09 Regents Of The University Of Michigan, The Mineralization and cellular patterning on biomaterial surfaces

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227792B2 (en) * 2001-02-05 2007-12-13 Industrial Technology Research Institute Methods and devices for tissue repair

Also Published As

Publication number Publication date
WO2001035932A2 (en) 2001-05-25
WO2001035932A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
EP1180378B8 (en) Nasal delivery device
AU749892C (en) Drug delivery system using membrane mimetics
EP1228071B8 (en) Pharmaceutically active isoindoline derivatives
AU782409C (en) Pharmaceutically active isoindoline derivatives
AU777410C (en) Preserved pharmaceutical formulations
HK1048428A1 (en) Ophthalmic drug delivery device.
ZA200201189B (en) Ophthalmic drug delivery device.
ZA200203394B (en) Pharmaceutical compositions.
AU7839900A (en) Reusable medication delivery device
ZA200108127B (en) Pharmaceutical compounds.
ZA200200628B (en) Pharmaceutical compounds.
HK1079718A1 (en) Intracardiac drug delivery
AU2002244142A1 (en) Integrated medication delivery system
HK1050367A1 (en) Pharmaceutically active compounds.
HK1045650A1 (en) Pharmaceutical composition.
AU2853700A (en) Sustained delivery of polyionic bioactive agents
AU4792499A (en) Enhanced call delivery system
AU6876498A (en) Intravesical drug delivery system
AU7837800A (en) Rapid infusion system
AU7333601A (en) Drug delivery management system
PL357535A1 (en) Hydrogel-driven drug dosage form
AU1206597A (en) Gastrointestinal drug delivery system
GB9700624D0 (en) Drug delivery composition
IL158527D0 (en) Sustained release drug delivery system containing codrugs
AU5335698A (en) Pharmaceutical formulations with delayed drug release

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase